Pegdinetanib

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NamePegdinetanib
Drug Alias NameAngioceptBMS-844203CT-322ATI-1249
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionVascular endothelial growth factor receptor 2 antagonists
TargetsVascular endothelial growth factor receptor 2
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsGlioma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBristol-Myers Squibb Company
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsGlioma +[4] 

Other Information

ATC CodeN/A
Related LinksN/A